drugset / Trial / NCT06328491
Erdafitinib in Metastatic Steroid-cell Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single participant study of erdafitinib for the treatment of a patient with metastatic steroid-cell tumor of the ovary.
Timeline
- Start
- 2022-05-30
- Primary completion
- 2022-08-22
- Completion
- 2022-08-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erdafitinib | Small molecule | 8 mg | Oral |